Controlling Childhood Myopia Progression: A Systematic Review of Interventions
Journal of Ophthalmic and Optometric Sciences,
Vol. 9 No. 2 (2025),
5 Farvardin 2025
,
Page 44-56
https://doi.org/10.22037/joos.v9i2.50684
Abstract
Purpose: To synthesize evidence on risk factors and interventions for slowing myopia progression in children and adolescents.
Methods: PubMed, Scopus, Embase, and Web of Science were searched through December 2023. Eligible studies included randomized and observational designs evaluating environmental factors, specialized spectacle lenses (defocus incorporated multiple segments [DIMS], highly aspherical lens [HAL], slightly aspherical lens [SAL]), multifocal or dual-focus soft contact lenses, orthokeratology, low-dose atropine, and repeated low-level red-light therapy. Two reviewers independently screened and extracted data. Risk of bias was assessed with Cochrane RoB 2 for randomized trials and the Newcastle–Ottawa Scale for observational studies. Outcomes were annual change in spherical equivalent refraction (diopters/year) and axial length (millimeters/year).
Results: Increased outdoor time was consistently associated with reduced incidence and slower progression. Specialized spectacle lenses (DIMS, HAL, SAL) and dual-focus/multifocal soft contact lenses slowed refractive change and axial elongation compared with single-vision controls. Orthokeratology effectively reduced axial elongation in appropriately selected eyes. Low-dose atropine produced dose-dependent benefits, with 0.05% generally more effective than 0.01%; rebound varied with dose, treatment duration, and tapering. Emerging evidence for red-light therapy suggested short-term efficacy, but long-term safety and rebound remain uncertain. Combination strategies, such as atropine plus optical interventions, showed additive effects, though data are limited.
Conclusions: Outdoor exposure, low-dose atropine (≈0.05%), DIMS/HAL/SAL spectacle lenses, multifocal or dual-focus soft contact lenses, and orthokeratology show the strongest evidence for slowing childhood myopia. Combination therapy may enhance outcomes, while red-light therapy remains promising but investigational, with long-term safety and rebound still uncertain.
- Myopia
- Disease Progression
- Child
- Adolescent
- Orthokeratologic Procedures
- Atropine/therapeutic use
How to Cite
References
Eppenberger LS, Sturm V. The Role of Time Exposed to Outdoor Light for Myopia Prevalence and Progression: A Literature Review. Clin Ophthalmol. 2020;14:1875-90.
Wang J, Li Y, Musch DC, Wei N, Qi X, Ding G, et al. Progression of Myopia in School-Aged Children After COVID-19 Home Confinement. JAMA Ophthalmol. 2021;139(3):293-300.
Jonas JB, Ang M, Cho P, Guggenheim JA, He MG, Jong M, et al. IMI Prevention of Myopia and Its Progression. Invest Ophthalmol Vis Sci. 2021;62(5):6.
Baird PN, Saw SM, Lanca C, Guggenheim JA, Smith Iii EL, Zhou X, et al. Myopia. Nat Rev Dis Primers. 2020;6(1):99.
Grzybowski A, Kanclerz P, Tsubota K, Lanca C, Saw SM. A review on the epidemiology of myopia in school children worldwide. BMC Ophthalmol. 2020;20(1):27.
Dong L, Kang YK, Li Y, Wei WB, Jonas JB. Prevalence and Time Trends of Myopia In Children and Adoltsents in China: A Ssstematic Review and Meta-Analysis. Retina. 2020;40(3):399-411.
Jones-Jordan LA, Sinnott LT, Chu RH, Cotter SA, Kleinstein RN, Manny RE, et al. Myopia Progression as a Function of Sex, Age, and Ethnicity. Invest Ophthalmol Vis Sci. 2021;62(10):36.
Pärssinen O, Era P, Leskinen AL. Some physiological and psychological characteristics of myopic and non-myopic young men. Acta Ophthalmol Suppl (1985). 1985;173:85-7.
Yazdani N, Sadeghi R, Ehsaei A, Taghipour A, Hasanzadeh S, Zarifmahmoudi L, et al. Under-correction or full correction of myopia? A meta-analysis. J Optom. 2021;14(1):11-19.
Liu Y, Wildsoet C. The effect of two-zone concentric bifocal spectacle lenses on refractive error development and eye growth in young chicks. Invest Ophthalmol Vis Sci. 2011;52(2):1078-86.
Arumugam B, Hung LF, To CH, Holden B, Smith EL 3rd. The effects of simultaneous dual focus lenses on refractive development in infant monkeys. Invest Ophthalmol Vis Sci. 2014;55(11):7423-32.
Wallman J, Winawer J. Homeostasis of eye growth and the question of myopia. Neuron. 2004;43(4):447-68.
Tse DY, Lam CS, Guggenheim JA, Lam C, Li KK, Liu Q, et al. Simultaneous defocus integration during refractive development. Invest Ophthalmol Vis Sci. 2007;48(12):5352-9.
Russo A, Boldini A, Romano D, Mazza G, Bignotti S, Morescalchi F, et al. Myopia: Mechanisms and Strategies to Slow Down Its Progression. J Ophthalmol. 2022;2022:1004977.
Guo H, Li X, Zhang X, Wang H, Li J. Comparing the effects of highly aspherical lenslets versus defocus incorporated multiple segment spectacle lenses on myopia control. Sci Rep. 2023;13(1):3048.
Lam CS, Tang WC, Tse DY, Tang YY, To CH. Defocus Incorporated Soft Contact (DISC) lens slows myopia progression in Hong Kong Chinese schoolchildren: a 2-year randomised clinical trial. Br J Ophthalmol. 2014;98(1):40-5.
Nio YK, Jansonius NM, Wijdh RH, Beekhuis WH, Worst JG, Norrby S, et al. Effect of methods of myopia correction on visual acuity, contrast sensitivity, and depth of focus. J Cataract Refract Surg. 2003;29(11):2082-95.
Wang G, Zhang Y, Zhao J, Zhang J, Jiang F. Mitigate the effects of home confinement on children during the COVID-19 outbreak. Lancet. 2020;395(10228):945-7.
Lawrenson JG, Shah R, Huntjens B, Downie LE, Virgili G, Dhakal R, et al. Interventions for myopia control in children: a living systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023;2(2):CD014758.
Jan C, Xu R, Luo D, Xiong X, Song Y, Ma J, et al. Association of Visual Impairment With Economic Development Among Chinese Schoolchildren. JAMA Pediatr. 2019;173(7):e190914.
Li T, Wei R, Du B, Wu Q, Yan J, Meng X, et al. Prevalence of myopia among children and adolescents aged 6-16 during COVID-19 pandemic: a large-scale cross-sectional study in Tianjin, China. Br J Ophthalmol. 2024;108(6):879-83.
Morgan IG, Jan CL. China Turns to School Reform to Control the Myopia Epidemic: A Narrative Review. Asia Pac J Ophthalmol (Phila). 2022;11(1):27-35.
Ma Y, Lin S, Li L, Jia Y, Zou H. Socioeconomic mechanisms of myopia boom in China: a nationwide cross-sectional study. BMJ open. 2021;11(6):e044608.
Zhang X, Cheung SSL, Chan HN, Zhang Y, Wang YM, Yip BH, et al. Myopia incidence and lifestyle changes among school children during the COVID-19 pandemic: a population-based prospective study. Br J Ophthalmol. 2022;106(12):1772-8.
Mohan A, Sen P, Peeush P, Shah C, Jain E. Impact of online classes and home confinement on myopia progression in children during COVID-19 pandemic: Digital eye strain among kids (DESK) study 4. Indian J Ophthalmol. 2022;70(1):241-5.
Lingham G, Mackey DA, Lucas R, Yazar S. How does spending time outdoors protect against myopia? A review. Br J Ophthalmol. 2020;104(5):593-9.
Li T, Wei R, Du B, Wu Q, Yan J, Meng X, et al. Prevalence of myopia among children and adolescents aged 6-16 during COVID-19 pandemic: a large-scale cross-sectional study in Tianjin, China. Br J Ophthalmol. 2024;108(6):879-83.
Guo Y, Liu L, Lv Y, Tang P, Feng Y, Wu M, et al. Outdoor Jogging and Myopia Progression in School Children From Rural Beijing: The Beijing Children Eye Study. Transl Vis Sci Technol. 2019;8(3):2.
VanderVeen DK, Kraker RT, Pineles SL, Hutchinson AK, Wilson LB, Galvin JA, et al. Use of Orthokeratology for the Prevention of Myopic Progression in Children: A Report by the American Academy of Ophthalmology. Ophthalmology. 2019;126(4):623-36.
Morgan IG, Wu PC, Ostrin LA, Tideman JWL, Yam JC, Lan W, et al. IMI Risk Factors for Myopia. Invest Ophthalmol Vis Sci. 2021;62(5):3.
Yang YC, Hsu NW, Wang CY, Shyong MP, Tsai DC. Prevalence Trend of Myopia after Promoting Eye Care in Preschoolers: A Serial Survey in Taiwan before and during the Coronavirus Disease 2019 Pandemic. Ophthalmology. 2022;129(2):181-90.
Wei R, Lu D, Jin N, Du B. Interpretation of the International Myopia Institute white papers focusing on myopia prevention and control. Recent Advances in Ophthalmology. 2019;39(8):701-13.
Li SM, Wei S, Atchison DA, Kang MT, Liu L, Li H, et al. Annual Incidences and Progressions of Myopia and High Myopia in Chinese Schoolchildren Based on a 5-Year Cohort Study. Invest Ophthalmol Vis Sci. 2022;63(1):8.
Ma Y, Zou H, Lin S, Xu X, Zhao R, Lu L, et al. Cohort study with 4-year follow-up of myopia and refractive parameters in primary schoolchildren in Baoshan District, Shanghai. Clin Exp Ophthalmol. 2018;46(8):861-72.
Wang J, Qi Z, Feng Y, Chen J, Du L, Yang J, et al. Normative value of hyperopia reserve and myopic shift in Chinese children and adolescents aged 3-16 years. Br J Ophthalmol. 2024;108(7):1024-9.
Bullimore MA, Ritchey ER, Shah S, Leveziel N, Bourne RRA, Flitcroft DI. The Risks and Benefits of Myopia Control. Ophthalmology. 2021;128(11):1561-79.
Walline JJ, Lindsley KB, Vedula SS, Cotter SA, Mutti DO, Ng SM, et al. Interventions to slow progression of myopia in children. Cochrane Database Syst Rev. 2020;1(1):CD004916.
Zhang X, Wang Y, Zhou X, Qu X. Analysis of Factors That May Affect the Effect of Atropine 0.01% on Myopia Control. Front Pharmacol. 2020;11:01081.
Ha A, Kim SJ, Shim SR, Kim YK, Jung JH. Efficacy and Safety of 8 Atropine Concentrations for Myopia Control in Children: A Network Meta-Analysis. Ophthalmology. 2022;129(3):322-33.
Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology. 2019;126(1):113-24.
Yu M, Jiang L, Chen M. Effect of atropine 0.01% on myopia control in children aged 6-13 years during the 2022 lockdown in Shanghai. Front Public Health. 2023;11:1074272.
Lam CS, Tang WC, Lee PH, Zhang HY, Qi H, Hasegawa K, et al. Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. Br J Ophthalmol. 2022;106(8):1110-14.
Guimarães S, Barros da Silva P, Oliveiros B, Silva E. Myopia control: short-term effect of 0.01% atropine vs. defocus incorporated multiple segment lenses-a retrospective study in European children. Int Ophthalmol. 2023;43(10):3777-84.
Akagün N, Altıparmak UE. Combination Therapy with Atropine 0.05% and Myopi-X® Glasses: Is it Effective in Myopia Control? Turk J Ophthalmol. 2025;55(1):1-5.
Xu H, Ye L, Peng Y, Yu T, Li S, Weng S, et al. Potential Choroidal Mechanisms Underlying Atropine's Antimyopic and Rebound Effects: A Mediation Analysis in a Randomized Clinical Trial. Invest Ophthalmol Vis Sci. 2023;64(4):13.
Yam JC, Jiang Y, Lee J, Li S, Zhang Y, Sun W, et al. The Association of Choroidal Thickening by Atropine With Treatment Effects for Myopia: Two-Year Clinical Trial of the Low-concentration Atropine for Myopia Progression (LAMP) Study. Am J Ophthalmol. 2022;237:130-8.
Ye L, Shi Y, Yin Y, Li S, He J, Zhu J, et al. Effects of Atropine Treatment on Choroidal Thickness in Myopic Children. Invest Ophthalmol Vis Sci. 2020;61(14):15.
Xiong S, He X, Zhang B, Deng J, Wang J, Lv M, et al. Changes in Choroidal Thickness Varied by Age and Refraction in Children and Adolescents: A 1-Year Longitudinal Study. Am J Ophthalmol. 2020;213:46-56.
Lee SH, Tsai PC, Chiu YC, Wang JH, Chiu CJ. Myopia progression after cessation of atropine in children: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1343698.
Repka MX, Weise KK, Chandler DL, Wu R, Melia BM, Manny RE, et al. Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial. JAMA Ophthalmol. 2023;141(8):756-65.
Wei S, Li SM, An W, Du J, Liang X, Sun Y, et al. Myopia progression after cessation of low-dose atropine eyedrops treatment: A two-year randomized, double-masked, placebo-controlled, cross-over trial. Acta Ophthalmol. 2023;101(2):e177-84.
Zadnik K, Schulman E, Flitcroft I, Fogt JS, Blumenfeld LC, Fong TM, et al. Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial. JAMA Ophthalmol. 2023;141(10):990-9.
Erdinest N, London N, Levinger N, Lavy I, Pras E, Morad Y. Decreased effectiveness of 0.01% atropine treatment for myopia control during prolonged COVID-19 lockdowns. Cont Lens Anterior Eye. 2022;45(4):101475.
Erdinest N, London N, Lavy I, Levinger N, Pras E, Morad Y. Myopia control utilizing low-dose atropine as an isolated therapy or in combination with other optical measures: A retrospective cohort study. Taiwan J Ophthalmol. 2022;13(2):231-7.
Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119(2):347-54.
Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, et al. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report. Ophthalmology. 2022;129(3):308-21.
Tong L, Huang XL, Koh AL, Zhang X, Tan DT, Chua WH. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. Ophthalmology. 2009;116(3):572-9.
Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops. Ophthalmology. 2016;123(2):391-9.
Wu PC, Chuang MN, Choi J, Chen H, Wu G, Ohno-Matsui K, et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond). 2019;33(1):3-13.
Gong Q, Janowski M, Luo M, Wei H, Chen B, Yang G, et al. Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis. JAMA Ophthalmol. 2017;135(6):624-30.
Huang J, Mutti DO, Jones-Jordan LA, Walline JJ. Bifocal & Atropine in Myopia Study: Baseline Data and Methods. Optom Vis Sci. 2019;96(5):335-44.
Jones JH, Mutti DO, Jones-Jordan LA, Walline JJ. Effect of Combining 0.01% Atropine with Soft Multifocal Contact Lenses on Myopia Progression in Children. Optom Vis Sci. 2022;99(5):434-42.
Tan Q, Ng AL, Choy BN, Cheng GP, Woo VC, Cho P. One-year results of 0.01% atropine with orthokeratology (AOK) study: a randomised clinical trial. Ophthalmic Physiol Opt. 2020;40(5):557-66.
Kang P. Optical and pharmacological strategies of myopia control. Clin Exp Optom. 2018;101(3):321-32.
Yue PC, Kong L, Zhang T, Qiao ZT. Research progress on the application of specially lense related to myopia prevention and control. Zhonghua Yan Ke Za Zhi. 2024;60(4):384-91. (Article in Chinease)
Bao J, Huang Y, Li X, Yang A, Zhou F, Wu J, et al. Spectacle Lenses With Aspherical Lenslets for Myopia Control vs Single-Vision Spectacle Lenses: A Randomized Clinical Trial. JAMA Ophthalmol. 2022;140(5):472-8.
Garcia-Del Valle AM, Blázquez V, Gros-Otero J, Infante M, Culebras A, Verdejo A, et al. Efficacy and safety of a soft contact lens to control myopia progression. Clin Exp Optom. 2021;104(1):14-21.
Li X, Huang Y, Yin Z, Liu C, Zhang S, Yang A, et al. Myopia Control Efficacy of Spectacle Lenses With Aspherical Lenslets: Results of a 3-Year Follow-Up Study. Am J Ophthalmol. 202;253:160-8.
Zhao Y, Yang B, Li X, Ma W, Liu L, Yan N. Efficacy of Combining Highly Aspherical Lenslets Spectacles With 0.01% Atropine Eye Drops in Myopia Control. Sichuan Da Xue Xue Bao Yi Xue Ban. 2024;55(5):1280-7. (Article in Chinese)
Erdinest N, Atar-Vardi M, London N, Landau D, Smadja D, Pras E, et al. Treatment of Rapid Progression of Myopia: Topical Atropine 0.05% and MF60 Contact Lenses. Vision. 2024;8(1):3.
Erdinest N, London N, Lavy I, Landau D, Ben Ephraim Noyman D, Levinger N, et al. Low-Concentration Atropine Monotherapy vs. Combined with MiSight 1 Day Contact Lenses for Myopia Management. Vision (Basel). 2022;6(4): 73.
Nucci P, Lembo A, Schiavetti I, Shah R, Edgar DF, Evans BJW. A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS/atropine. PloS one. 2023;18(2):e0281816.
Jiang Y, Zhu Z, Tan X, Kong X, Zhong H, Zhang J, et al. Effect of Repeated Low-Level Red-Light Therapy for Myopia Control in Children: A Multicenter Randomized Controlled Trial. Ophthalmology. 2022;129(5):509-19.
Xiong R, Zhu Z, Jiang Y, Wang W, Zhang J, Chen Y, et al. Longitudinal Changes and Predictive Value of Choroidal Thickness for Myopia Control after Repeated Low-Level Red-Light Therapy. Ophthalmology. 2023;130(3):286-96.
Chen H, Wang W, Liao Y, Zhou W, Li Q, Wang J, et al. Low-intensity red-light therapy in slowing myopic progression and the rebound effect after its cessation in Chinese children: a randomized controlled trial. Graefes Arch Clin Exp Ophthalmol. 2023;261(2):575-84.
Dong J, Zhu Z, Xu H, He M. Myopia Control Effect of Repeated Low-Level Red-Light Therapy in Chinese Children: A Randomized, Double-Blind, Controlled Clinical Trial. Ophthalmology. 2023;130(2):198-204.
Xiong R, Zhu Z, Jiang Y, Kong X, Zhang J, Wang W, et al. Sustained and rebound effect of repeated low-level red-light therapy on myopia control: A 2-year post-trial follow-up study. Clin Exp Ophthalmol. 2022;50(9):1013-24.
Hiraoka T, Sekine Y, Okamoto F, Mihashi T, Oshika T. Safety and efficacy following 10-years of overnight orthokeratology for myopia control. Ophthalmic Physiol Opt. 2018;38(3):281-9.
Hiraoka T. Myopia Control With Orthokeratology: A Review. Eye Contact Lens. 2022;48(3):100-4.
Tan Q, Ng AL, Cheng GP, Woo VC, Cho P. Combined 0.01% atropine with orthokeratology in childhood myopia control (AOK) study: A 2-year randomized clinical trial. Cont Lens Anterior Eye. 2023;46(1):101723.
Li B, Yu S, Gao S, Sun G, Pang X, Li X, et al. Effect of 0.01% atropine combined with orthokeratology lens on axial elongation: a 2-year randomized, double-masked, placebo-controlled, cross-over trial. Front Med (Lausanne). 2024;11:1358046.
Cho P, Tan Q. Myopia and orthokeratology for myopia control. Clin Exp Optom. 2019;102(4):364-77.
Chen C, Cheung SW, Cho P. Myopia control using toric orthokeratology (TO-SEE study). Invest Ophthalmol Vis Sci. 2013;54(10):6510-7.
Si JK, Tang K, Bi HS, Guo DD, Guo JG, Wang XR. Orthokeratology for myopia control: a meta-analysis. Optom Vis Sci. 2015;92(3):252-7.
Lipson MJ, Brooks MM, Koffler BH. The Role of Orthokeratology in Myopia Control: A Review. Eye Contact Lens. 2018;44(4):224-30.
- Abstract Viewed: 183 times
- pdf Downloaded: 196 times
